Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

– Subjects in Herniorrhaphy Study Dosed – Successful FDA Interactions on Two Pre-clinical Pipeline Products Also Discussed SAN DIEGO, April 18, 2023 /PRNewswire/ — Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali” or “Cali Biosciences”), a biopharmaceutical company focused on…